<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

Default sub title

minute read

by TCTMD | August 19, 2024
placeholder

Patients with PAD who meet criteria for frailty can reap similar benefits as their nonfrail counterparts when prescribed a combination of low-dose direct oral anticoagulant and aspirin following lower extremity revascularization, an analysis of the VOYAGER-PAD trial shows.

Topics: Press Coverage